| 1.95 -0.04 (-2.01%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.75  |
1-year : | 3.04 |
| Resists | First : | 2.35 |
Second : | 2.6 |
| Pivot price | 2.18 |
|||
| Supports | First : | 1.95 |
Second : | 1.62 |
| MAs | MA(5) : | 2.05 |
MA(20) : | 2.21 |
| MA(100) : | 2.34 |
MA(250) : | 3.04 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.8 |
D(3) : | 14.3 |
| RSI | RSI(14): 26 |
|||
| 52-week | High : | 4.71 | Low : | 1.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TXMD ] has closed below the lower bollinger band by 5.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.08 | 2.08 - 2.1 |
| Low: | 1.91 - 1.93 | 1.93 - 1.95 |
| Close: | 1.92 - 1.96 | 1.96 - 1.99 |
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Sat, 13 Apr 2024
StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
Mon, 01 Apr 2024
TherapeuticsMD Inc (TXMD) Stock Gains 2.62% This Week: Is It a Good Pick? - InvestorsObserver
Fri, 29 Mar 2024
TherapeuticsMD Announces 2023 Annual Financial Results - TipRanks.com - TipRanks
Tue, 26 Mar 2024
TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com - Defense World
Mon, 18 Mar 2024
TherapeuticsMD Inc (TXMD) Stock Gains 9.87% This Week: Is It a Good Pick? - InvestorsObserver
Mon, 18 Mar 2024
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 3.7 (%) |
| Held by Institutions | 28.2 (%) |
| Shares Short | 45 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.53 |
| Profit Margin | 0 % |
| Operating Margin | -321 % |
| Return on Assets (ttm) | -8 % |
| Return on Equity (ttm) | -23.9 % |
| Qtrly Rev. Growth | -99.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -34 (M) |
| PE Ratio | -2.64 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 17.29 |
| Price to Cash Flow | -0.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|